Global RAS-Targeting Drugs for Precision Oncology Market Size is predicted to grow with a 11.9% CAGR during the forecast period for 2025-2034.
The RAS-targeting medicines in precision oncology is a fast-developing area dedicated to treatments that block RAS proteins—indispensable molecular promoters in aggressive forms of cancer such as lung, colorectal, and pancreatic cancer. RAS gene mutations (KRAS, NRAS, and HRAS) are some of the most frequent in cancer and result in perpetual stimulation of signaling cascades driving tumor growth. Previously considered "undruggable" because of their structural sophistication, recent advances—most notably the discovery of direct KRAS G12C inhibitors—have transformed treatment options and set the stage for novel RAS-targeting agent classes, including small-molecule inhibitors, allosteric modulators, and protein degraders.
The attractiveness of RAS-targeting medicines is their promise to provide personalized cancer therapies based on an individual's tumor genotype, enhancing efficacy with decreased toxicity. This has led to a huge investment by large pharma and biotech companies. Top market drivers are the worldwide increase in RAS-mutant cancers, improved molecular diagnostics for accurate identification of the patient, and ongoing innovation in drug development. Nevertheless, the market continues to face challenges owing to the inherent difficulty of targeting RAS proteins, which are structurally inscrutable to many therapeutic modalities.
Some of the Key Players in RAS-Targeting Drugs for Precision Oncology Market:
The RAS-targeting drugs for precision oncology industry is segmented by drug type, target mutation, indication, route of administration. By drug type, the market is segmented into small molecule inhibitors, biologics, RNA-based therapies, combination therapies. By Target Mutation, it is segmented into KRAS G12C, KRAS G12D, KRAS G12V, G12R, G12S, G12A, HRAS and NRAS, Pan-RAS. By distribution channel market is segmented into non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), other cancers (e.g., HNSCC, melanoma, hematologic). By route of administration market is segmented into oral, intravenous, other routes.
The precision oncology market for RAS-targeting drugs is led mainly by the small molecule inhibitors segment, with KRAS G12C inhibitors sotorasib and adagrasib gaining significant clinical as well as commercial success. The inhibitors are favored due to their specificity in targeting mutant RAS proteins, ease of formulation, and affordability relative to biologics. Though biologics, RNA therapies, and combinations are under development and driving market growth, small molecule inhibitors are ahead for now with their regulatory approvals, proven efficacy, and widespread application against RAS-mutated cancers like non-small cell lung cancer and colorectal cancer. Though combination treatments are promising, especially in their potential to overcome drug resistance, those are still primarily in clinical trials and haven't had a tangible effect on the market yet.
The fastest-growing indication in the RAS-targeting drugs market is the non-small cell lung cancer (NSCLC) segment, led by the breakthrough approvals of KRAS G12C inhibitors sotorasib (Lumakras) and adagrasib (Krazati), which have revolutionized treatment for patients with previously untargetable mutations. Rapid clinical uptake is aided by continuous innovation, such as combination approaches with immunotherapies to boost outcomes and circumvent resistance. With KRAS mutations, and most notably G12C, prevalent in NSCLC and the worldwide disease burden high, this segment enjoys substantial unmet need. Moreover, technical advances in molecular diagnostics have enabled standard mutation testing, guaranteeing that eligible patients are identified and matched to these agents, driving rapid market growth.
North America, particularly the United States, is leading the upcycled ingredients market in the beverage sector due to high food waste and excess byproducts such as spent grains and dairy whey. The abundance of raw materials enables large-scale upcycling. Robust consumer interest in sustainable, environmentally friendly products has prompted the use of upcycled ingredients in functional, spirits, and plant-based milks. Innovation and investment by large brands and startups, as well as certification by organizations such as the Upcycled Food Association, are further driving market growth. Also, regulations and transparency measures are facilitating adoption and sale of upcycled ingredients by companies, making the U.S. a leader in this area even stronger.
| Report Attribute | Specifications |
| Growth Rate CAGR | CAGR of 11.9 % from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Bn and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2023 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Drug Type, Target Mutation, Indication, Route of Administration and By Region |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | Amgen, Mirati Therapeutics, Revolution Medicines, Verastem Oncology, Novartis, Kura Oncology, Elicio Therapeutics, Jacobio Pharmaceuticals, Onconova Therapeutics, Targovax, Genfleet Therapeutics, Golden Biotechnology, Roche, Nested Therapeutics, AnBogen, AstraZeneca |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
| Pricing and Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Segmentation of RAS-Targeting Drugs for Precision Oncology Market -
RAS-Targeting Drugs for Precision Oncology by Drug Type -
RAS-Targeting Drugs for Precision Oncology by Target Mutation -
RAS-Targeting Drugs for Precision Oncology by Indication -
RAS-Targeting Drugs for Precision Oncology by Route of Administration -
RAS-Targeting Drugs for Precision Oncology by Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global RAS-Targeting Drugs for Precision Oncology Market Snapshot
Chapter 4. Global RAS-Targeting Drugs for Precision Oncology Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Competitive Landscape & Market Share Analysis, By Key Player (2023)
4.9. Use/impact of AI on RAS-Targeting Drugs for Precision Oncology Market Trends
4.10. Global RAS-Targeting Drugs for Precision Oncology Market Penetration & Growth Prospect Mapping (US$ Mn), 2021-2034
Chapter 5. RAS-Targeting Drugs for Precision Oncology Market Segmentation 1: By Drug Type, Estimates & Trend Analysis
5.1. Market Share by Drug Type, 2024 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Drug Type:
5.2.1. Small Molecule Inhibitors
5.2.2. Biologics
5.2.3. RNA-Based Therapies
5.2.4. Combination Therapies
Chapter 6. RAS-Targeting Drugs for Precision Oncology Market Segmentation 2: Target Mutation, Estimates & Trend Analysis
6.1. Market Share by Target Mutation, 2024 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Target Mutation:
6.2.1 KRAS G12C
6.2.2 KRAS G12D
6.2.3 KRAS G12V, G12R, G12S, G12A
6.2.4 HRAS and NRAS
6.2.5 Pan-RAS
Chapter 7. RAS-Targeting Drugs for Precision Oncology Market Segmentation 3: By Indication, Estimates & Trend Analysis
7.1. Market Share by Indication, 2024 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Indication:
7.2.1. Non-Small Cell Lung Cancer (NSCLC)
7.2.2. Pancreatic Ductal Adenocarcinoma (PDAC)
7.2.3. Colorectal Cancer (CRC)
7.2.4. Other Cancers (e.g., HNSCC, melanoma, hematologic)
Chapter 8. RAS-Targeting Drugs for Precision Oncology Market Segmentation 4: By Route of Administration, Estimates & Trend Analysis
8.1. Market Share by Route of Administration, 2024 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Route of Administration:
8.2.1. Oral
8.2.2. Intravenous
8.2.3. Other Routes
Chapter 9. RAS-Targeting Drugs for Precision Oncology Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. Global RAS-Targeting Drugs for Precision Oncology Market, Regional Snapshot 2024 & 2034
9.2. North America
9.2.1. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.2.1.1. US
9.2.1.2. Canada
9.2.2. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.2.3. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.2.4. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.2.5. North America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.3. Europe
9.3.1. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.3.1.1. Germany
9.3.1.2. U.K.
9.3.1.3. France
9.3.1.4. Italy
9.3.1.5. Spain
9.3.1.6. Rest of Europe
9.3.2. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.3.3. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.3.4. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.3.5. Europe RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.4. Asia Pacific
9.4.1. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.4.1.1. India
9.4.1.2. China
9.4.1.3. Japan
9.4.1.4. Australia
9.4.1.5. South Korea
9.4.1.6. Hong Kong
9.4.1.7. Southeast Asia
9.4.1.8. Rest of Asia Pacific
9.4.2. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.4.3. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.4.4. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.4.5. Asia Pacific RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.5. Latin America
9.5.1. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Country, 2021-2034
9.5.1.1. Brazil
9.5.1.2. Mexico
9.5.1.3. Rest of Latin America
9.5.2. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.5.3. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.5.4. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.5.5. Latin America RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.6. Middle East & Africa
9.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.6.1.1. GCC Countries
9.6.1.2. Israel
9.6.1.3. South Africa
9.6.1.4. Rest of Middle East and Africa
9.6.2. Middle East & Africa RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Drug Type, 2021-2034
9.6.3. Middle East & Africa RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Target Mutation, 2021-2034
9.6.4. Middle East & Africa RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.6.5. Middle East & Africa RAS-Targeting Drugs for Precision Oncology Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Amgen
10.2.1.1. Business Overview
10.2.1.2. Key Drug Type/Service Overview
10.2.1.3. Financial Performance
10.2.1.4. Geographical Presence
10.2.1.5. Recent Developments with Business Strategy
10.2.2. Mirati Therapeutics
10.2.3. Revolution Medicines
10.2.4. Verastem Oncology
10.2.5. Novartis
10.2.6. Kura Oncology
10.2.7. Elicio Therapeutics
10.2.8. Jacobio Pharmaceuticals
10.2.9. Onconova Therapeutics
10.2.10. Targovax
10.2.11. Genfleet Therapeutics
10.2.12. Golden Biotechnology
10.2.13. Roche
10.2.14. Nested Therapeutics
10.2.15. AnBogen
10.2.16. AstraZeneca